Marcos Malumbres studied in the University of Navarra and performed his doctoral studies in the University of León, working in molecular genetics in gram-positive bacteria. After obtaining the Ph.D. degree, he moved for a postdoctoral stay at the New York University Medical Center for training in the field of oncogenes and tumor suppressors. In this institution, his work focused on the molecular biology of Ras oncogenes in carcinogen-induced tumors and the interaction between Ras and the cell cycle regulators in collaboration with A. Pellicer (1994-1998). Dr. Malumbres returned to Spain at the end of 1998 to join M. Barbacid’s lab in the then newly created CNIO. His research focused on the generation of mouse models to analyze the in vivo role of cyclin dependent kinases (CDKs) and their inhibitors in cell cycle progression and tumour development. In 2003 he obtained a Staff Scientist position at the Consejo Superior de Investigaciones Científicas (CSIC) and in June 2004 he decided to stay at the CNIO to lead the Cell Division and Cancer Group.
Dr. Malumbres’ lab is interested in the basic mechanisms that control cell proliferation and differentiation and their therapeutic potential. These studies have addressed the in vivo characterization of the mammalian cell cycle and their deregulation in human cancer with an initial focus on CDKs. Cdk4/6 inhibitors such as palbociclib have been recently (2015) approved for the treatment of breast tumors. Recent work in Malumbres’ lab focuses on the analysis of mitotic regulators and the specific energetic requirements of cancer cells during mitosis, supporting new combinatorial strategies targeting mitosis and glycolysis for cancer therapy. Current work includes the analysis of cell cycle kinases and phosphatases such as PP2A-B55 complexes, the regulatory networks between microRNAs and the cell division cycle and its relevance in progenitor cells and tumor development.